|
|
Volumn 17, Issue 2, 2000, Pages 54-59
|
|
Coronary disease, dyslipidaemia and clinical trials in type 2 diabetes mellitus
|
|
Author keywords
Clinical trials; Fibrates; Lipids; Statins; Treatment guidelines; Type 2 diabetes
|
|
Indexed keywords
ANTIBIOTIC AGENT;
ANTIHYPERTENSIVE AGENT;
ANTIINFLAMMATORY AGENT;
ANTILIPEMIC AGENT;
ANTIOXIDANT;
ATORVASTATIN;
BEZAFIBRATE;
DIHYDROPYRIDINE;
ESTROGEN;
FENOFIBRATE;
FIBRIC ACID DERIVATIVE;
FIBRINOLYTIC AGENT;
FIBRINOLYTIC FACTOR;
GEMFIBROZIL;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
IMMUNOMODULATING AGENT;
INSULIN;
LIPID;
LIPOPROTEIN;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
MARKER;
METFORMIN;
MEVINOLIN;
NICOTINIC ACID;
PRAVASTATIN;
SIMVASTATIN;
STATIN;
TRIACYLGLYCEROL;
TROGLITAZONE;
CLINICAL TRIAL;
CORONARY ARTERY DISEASE;
COST EFFECTIVENESS ANALYSIS;
DYSLIPIDEMIA;
FAT INTAKE;
HUMAN;
LIPID METABOLISM;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PRACTICE GUIDELINE;
REVIEW;
RISK FACTOR;
TREATMENT OUTCOME;
VASCULAR DISEASE;
|
|
EID: 0034063830
PISSN: 13578170
EISSN: None
Source Type: Journal
DOI: 10.1002/(SICI)1528-252X(200003/04)17:2<54::AID-PDI43>3.0.CO;2-1 Document Type: Review |
|
Times cited : (5)
|
|
References (38)
|
